Our data demonstrate that in DLBCL patients, CD73 is highly expressed on TN cells and minimally expressed on TEMRA CD8+ T cells, suggesting that the downregulation of CD73 is associated with the activation of an anti-tumor immune response by T cells. This evidence concerns the gene CD8A and diffuse large B-cell lymphoma.